GILEAD SCIENCES, INC. (GILD) FY2024 YTD Q3 P&L / Income Statement

GILEAD SCIENCES, INC. (GILD) FY2024 YTD Q3 P&L / Income Statement

Income statement for 2024-01-01 through 2024-09-30. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

21,185,000,000 US dollars

Cost of goods sold

4,670,000,000 US dollars

Gross profit (calculated)

16,515,000,000 US dollars

Operating expenses (calculated)

17,305,000,000 US dollars

Operating income (loss)

negative 790,000,000 US dollars

Other income (expense), net (calculated)

negative 687,000,000 US dollars

Income (loss) before income taxes

negative 1,477,000,000 US dollars

Income tax (benefit) expense

negative 174,000,000 US dollars

Net income (loss)

negative 1,303,000,000 US dollars

Tecartus

305,000,000 US dollars

Yescarta

1,181,000,000 US dollars

Biktarvy

9,649,000,000 US dollars

Descovy

1,496,000,000 US dollars

Genvoya

1,292,000,000 US dollars

Odefsey

952,000,000 US dollars

Symtuza - Revenue share

448,000,000 US dollars

Other HIV

322,000,000 US dollars

Sofosbuvir/Velpatasvir

1,266,000,000 US dollars

Vemlidy

699,000,000 US dollars

Other Liver Disease

337,000,000 US dollars

Trodelvy

960,000,000 US dollars

AmBisome

424,000,000 US dollars

Other

281,000,000 US dollars

Royalty, contract and other revenues

111,000,000 US dollars

Veklury

1,461,000,000 US dollars

Undisclosed (calculated)

1,000,000 US dollars

Selling, general and administrative expenses

4,184,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Acquired in-process research and development expenses

4,674,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Research and development expenses

4,266,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

In-process research and development impairment

4,180,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.